Lyell Immunopharma Stock News

Cubist Systematic Strategies LLC purchased a new position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) in the 2nd quarter, Holdings Channel.com reports. The firm purchased 5,807 shares of the companys stock, valued at approximately $94,000. Several other institutional investors and hedge funds have also recently modified their holdings of LYEL. Tudor Investment Corp Et Al []

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) gapped down prior to trading on Monday . The stock had previously closed at $10.81, but opened at $10.48. Lyell Immunopharma shares last traded at $10.49, with a volume of 2,265 shares trading hands. The companys 50 day simple moving average is $12.96. A number of institutional investors have []

Morgan Stanley purchased a new stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) during the 2nd quarter, HoldingsChannel.com reports. The firm purchased 1,646,846 shares of the companys stock, valued at approximately $26,745,000. A number of other institutional investors have also recently bought and sold shares of LYEL. Eagle Health Investments LP bought a new position in Lyell []

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients wi

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients wit

Shares of San Francisco-based Lyell Immunopharma Inc. , a clinical-stage biotech that is developing T cell therapies for solid tumors, stumbled in their trading debut Thursday, falling 2.2% at last ch

The companies are Verve Therapeutics, Lyell Immunopharma, iSpecimen and Angel Oak Mortgage.

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients wit